This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabino, M. A. C. Articles by Mantyh, P. W. Search for Related Content PubMed PubMed Citation Articles by Sabino, M. A. C. Articles by Mantyh, P. W.

Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Growth by Selective Inhibition of Cyclooxygenase-2¹

Neurosystems Center and Departments of Preventive Sciences, Psychiatry, Neuroscience, and Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455 and VA Medical Center, Minneapolis, Minnesota 55417 [M. A. C. S., J. R. G., J. L. M. J., C. P. K., N. M. L., D. B. M., C. M. P., S. D. R., M. J. S., P. W. M.], and Instituto de Neurociencias, Universidad Miguel Hernandez-Consejo Superior de Investigaciones Cientificas, Elehe 03202, Spain [C. d. F.]

More than half of all chronic cancer pain arises from metastases to bone, and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Several tumor types including sarcomas and breast, prostate, and lung carcinomas grow in or preferentially metastasize to the skeleton where they proliferate, and induce significant bone remodeling, bone destruction, and cancer pain. Many of these tumors express the isoenzyme cycloxygenase-2 (COX-2), which is involved in the synthesis of prostaglandins. To begin to define the role COX-2 plays in driving bone cancer pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined to the intramedullary space of the femur in male C3HHeJ mice. After tumor implantation, mice develop ongoing and movement-evoked bone cancer pain-related behaviors, extensive tumor-induced bone resorption, infiltration of the marrow space by tumor cells, and stereotypic neurochemical alterations in the spinal cord reflective of a persistent pain state. Thus, after injection of tumor cells, bone destruction is first evident at day 6, and pain-related behaviors are maximal at day 14. A selective COX-2 inhibitor was administered either acutely [NS398; 100 mg/kg, i.p.] on day 14 or chronically in chow {MF. tricyclic; 0.015%, p.o.} from day 6 to day 14 after tumor implantation. Acute administration of a selective COX-2 inhibitor attenuated both ongoing and movement-evoked bone cancer pain, whereas chronic inhibition of COX-2 significantly reduced ongoing and movement-evoked pain behaviors, and reduced tumor burden, osteoclastogenesis, and bone destruction by >50%. The present results suggest that chronic administration of a COX-2 inhibitor blocks prostaglandin synthesis at multiple sites, and may have significant clinical utility in the management of bone cancer and bone cancer pain.

This article has been cited by other articles:

				Y. Niiyama, T. Kawamata, J. Yamamoto, S. Furuse, and A. Namiki SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain Br. J. Anaesth., February 1, 2009; 102(2): 251 - 258. [Abstract] [Full Text] [PDF]

				T. Takahashi, H. Uehara, Y. Bando, and K. Izumi Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth Mol. Cancer Ther., September 1, 2008; 7(9): 2807 - 2816. [Abstract] [Full Text] [PDF]

				A. Delaney, S. M. Fleetwood-Walker, L. A. Colvin, and M. Fallon Translational medicine: cancer pain mechanisms and management Br. J. Anaesth., July 1, 2008; 101(1): 87 - 94. [Abstract] [Full Text] [PDF]

				R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]

				M. J. Goblirsch, P. P. Zwolak, and D. R. Clohisy Biology of bone cancer pain. Clin. Cancer Res., October 15, 2006; 12(20): 6231s - 6235s. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				J. R. Ghilardi, H. Rohrich, T. H. Lindsay, M. A. Sevcik, M. J. Schwei, K. Kubota, K. G. Halvorson, J. Poblete, S. R. Chaplan, A. E. Dubin, et al. Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain J. Neurosci., March 23, 2005; 25(12): 3126 - 3131. [Abstract] [Full Text] [PDF]

				C. Urch The pathophysiology of cancer-induced bone pain: current understanding Palliative Medicine, June 1, 2004; 18(4): 267 - 274. [Abstract] [PDF]

				B. A Watkins, Y. Li, H. E Lippman, S. Reinwald, and M. F Seifert A test of Ockham's razor: implications of conjugated linoleic acid in bone biology Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1175S - 1185S. [Abstract] [Full Text] [PDF]

				T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]

				M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al. Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422. [Abstract] [Full Text] [PDF]

				M. S. De Lorenzo, K. Yamaguchi, K. Subbaramaiah, and A. J. Dannenberg Bryostatin-1 Stimulates the Transcription of Cyclooxygenase-2: Evidence for an Activator Protein-1-Dependent Mechanism Clin. Cancer Res., October 15, 2003; 9(13): 5036 - 5043. [Abstract] [Full Text] [PDF]